{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:12:03Z","timestamp":1790777523551,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Neurosci Ther"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Mesial temporal lobe epilepsy (\n                      <jats:styled-content style=\"fixed-case\">MTLE<\/jats:styled-content>\n                      ) is the most common form of drug\u2010refractory epilepsy. Most of the morphological and electrophysiological features of human\n                      <jats:styled-content style=\"fixed-case\">MTLE<\/jats:styled-content>\n                      can be reproduced in a mouse by a unilateral intrahippocampal injection of kainate (\n                      <jats:styled-content style=\"fixed-case\">MTLE<\/jats:styled-content>\n                      mouse model). The effects of antiepileptic drugs (\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s) on the occurrence of recurrent focal hippocampal seizures in this model remain to be specified. Here, we addressed the pharmacological reactivity of this model to the most commonly used\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using depth electroencephalographical (\n                      <jats:styled-content style=\"fixed-case\">EEG<\/jats:styled-content>\n                      ) recordings, we tested the dose\u2013response effects of acute injection of nine\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s on the occurrence of hippocampal paroxysmal discharges (\n                      <jats:styled-content style=\"fixed-case\">HPD<\/jats:styled-content>\n                      s) as well as on ictal and interictal power spectra in the\n                      <jats:styled-content style=\"fixed-case\">MTLE<\/jats:styled-content>\n                      mouse model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Valproate, carbamazepine, and lamotrigine dose dependently suppressed\n                      <jats:styled-content style=\"fixed-case\">HPD<\/jats:styled-content>\n                      s and modified the general behavior and\/or\n                      <jats:styled-content style=\"fixed-case\">EEG<\/jats:styled-content>\n                      activity. Levetiracetam and pregabalin suppressed\n                      <jats:styled-content style=\"fixed-case\">HPD<\/jats:styled-content>\n                      s at high doses but without any behavioral nor interictal\n                      <jats:styled-content style=\"fixed-case\">EEG<\/jats:styled-content>\n                      changes. Finally, phenobarbital, tiagabine, vigabatrin, and diazepam suppressed\n                      <jats:styled-content style=\"fixed-case\">HPD<\/jats:styled-content>\n                      s in a dose\u2010dependent manner at doses devoid of obvious behavioral effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:styled-content style=\"fixed-case\">MTLE<\/jats:styled-content>\n                      mouse model displays a differential sensitivity to\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s with a greater efficacy of drug that facilitates\n                      <jats:styled-content style=\"fixed-case\">GABA<\/jats:styled-content>\n                      ergic transmission. This model provides an efficient tool to identify new treatment for drug\u2010resistant forms of focal epilepsies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cns.12523","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T04:00:39Z","timestamp":1456113639000},"page":"497-506","source":"Crossref","is-referenced-by-count":112,"title":["Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy"],"prefix":"10.1111","volume":"22","author":[{"given":"Venceslas","family":"Duveau","sequence":"first","affiliation":[{"name":"SynapCell SAS La Tronche France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Pouyatos","sequence":"additional","affiliation":[{"name":"SynapCell SAS La Tronche France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bressand","sequence":"additional","affiliation":[{"name":"SynapCell SAS La Tronche France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bouyssi\u00e8res","sequence":"additional","affiliation":[{"name":"SynapCell SAS La Tronche France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Chabrol","sequence":"additional","affiliation":[{"name":"INSERM U836 Grenoble France"},{"name":"University Grenoble Alpes Grenoble Institut des Neurosciences Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Roche","sequence":"additional","affiliation":[{"name":"SynapCell SAS La Tronche France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Depaulis","sequence":"additional","affiliation":[{"name":"INSERM U836 Grenoble France"},{"name":"University Grenoble Alpes Grenoble Institut des Neurosciences Grenoble France"},{"name":"CHU de Grenoble H\u00f4pital Michallon Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Roucard","sequence":"additional","affiliation":[{"name":"SynapCell SAS La Tronche France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004418"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00064-7"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2376"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh512"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuropharm.2014.11.008","article-title":"Inter\u2010individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice","volume":"90","author":"Klein S","year":"2014","journal-title":"Neuropharmacology"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.01.001"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.03603.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hipo.20793"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00302-3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1684\/epd.2012.0528","article-title":"Animal models to study aetiopathology of epilepsy: What are the features to model?","volume":"14","author":"Guillemain I","year":"2012","journal-title":"Epileptic Disord"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2015.01.558"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.09.002"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.02.013"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1109-10.2010"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-011-0039-z"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2005.00380.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2127"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.11.008"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1977.tb10721.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4126"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.11.001"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00065"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076510"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03018.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1988.tb03748.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207459309000566"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.05.003"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2009.04.007"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00410-5"},{"key":"e_1_2_7_31_1","doi-asserted-by":"crossref","unstructured":"StablesJP BertramE DudekFE et al.Therapy discovery for pharmacoresistant epilepsy and for disease\u2010modifying therapeutics: summary of the NIH\/NINDS\/AES models II workshop.2003. pages 1472\u20138.","DOI":"10.1111\/j.0013-9580.2003.32803.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2015.05.022"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcns.12523","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cns.12523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:49:35Z","timestamp":1695502175000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cns.12523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/cns.12523"],"URL":"https:\/\/doi.org\/10.1111\/cns.12523","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]}}}